Iridex announced new data was released at the World Ophthalmology Congress in Barcelona showing that MicroPulse Laser Therapy with the MicroPulse P3 Glaucoma Device is safe and effective. New real-world data shows a reduction in IOP close to 50%, with new morphological information elucidating the mechanism of action of the procedure.
Ihab Ibrahim Massad, FICO, MD, presented “No More Blades, Scars or Scares: A One Year Experience of MicroPulse Trans-scleral Cyclophotocoagulation from Middle East,” a retrospective chart review of 67 eyes that were treated with MP-TSCPC at a hospital in Jordan. The analysis found that IOP decreased close to 50%, from a mean preoperative IOP of 34.70 mmHg to a mean postoperative IOP of 18.32 mmHg at 1 month and 16.90 mmHg at 12 months. In addition, ocular hypertensive medication use was lowered from 3.45 medications to 2.64 medications at 1 month and 12 months. Only one-third of the eyes in the study had primary open-angle glaucoma, showing the flexibility of the procedure.
Shotar Asano, MD, and colleagues in Japan presented, “IOP Reduction and Morphological Changes of the Ciliary Body by MicroPulse Transscleral Cyclophotocoagulation.” The authors investigated postoperative morphological changes of the ciliary body using anterior segment optical coherence tomography (AS-OCT) in eight eyes with refractory glaucoma. AS-OCT analysis revealed that ciliochoroidal effusion (CE) was observed in four out of eight eyes in the inferior sclera at one day after the procedure, and all CE disappeared by two weeks after the procedure.
“It has long been understood that laser treatment of the ciliary processes will decrease production of aqueous humor,” Tim Buckley, Vice President of Global Marketing and Business Development at Iridex, said in a company news release. “This study shows that there may be an additional mechanism of action in play as well. This speaks to why MP-CPC works so well in a large variety of patients with different types of glaucoma.”